Biotechnology company AMAG Pharmaceuticals Inc. announced on May 12 that FDA regulators have accepted newly submitted data on its anemia drug candidate Feraheme (ferumoxytol). The treatment is intramuscular injected in order to treat iron deficiency in anemic patients with chronic kidney disease. The FDA is expected to rule on Feraheme by the end of June.